,922 $11.81 100.0% - Includes costs nal *Golly reined to programs above Sources. Company reports and %ma'am Emir 8 Company. L L.C. estimates 5 I Y. Katherine Xu, Ph.D. CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0 106554 SDNY_GM_00252738 EFTA01450729

al will be initiated to assess the long-term safety of Iclusig treatment, including the long-term risk of vascular occlusive events over time. 4 I Y. Katherine Xu, Ph.D. +1 212 237 2758 CONFIDENTIAL — PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0106553 CONFIDENTIAL SONY GM_00252737 EFTA01450728

www.williamblair.com. Please contact us at or consult williamblair.com/Research-a nd-Insights/Equ ity-Research/Coverage.aspx for all disclosures. Y. Katherine Xu attests that 1) all of the views expressed in this research report accurately reflect his/her personal views about any and all of the securities and

164,955 178,541 184,726 185,238 185,338 183,461 185,588 188,773 Sources: Company reports and William Blair & Company. L.L.C. estimates 6 I Y. Katherine Xu, Ph.D. CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0 106555 SDNY_GM_00252739 EFTA01450730